FALLOPIAN TUBE NEOPLASMS
Clinical trials for FALLOPIAN TUBE NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new FALLOPIAN TUBE NEOPLASMS trials appear
Sign up with your email to follow new studies for FALLOPIAN TUBE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental antibody boosts chemo in ovarian cancer trial
Disease control OngoingThis phase 2 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps control advanced ovarian, fallopian tube, or peritoneal cancer better than chemo alone. About 88 women with newly diagnosed stage III or …
Matched conditions: FALLOPIAN TUBE NEOPLASMS
Phase: PHASE2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Ovarian cancer hope: new antibody combo aims to delay disease worsening
Disease control OngoingThis Phase 3 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps people with newly diagnosed advanced ovarian cancer live longer without their cancer getting worse. About 615 participants who had surger…
Matched conditions: FALLOPIAN TUBE NEOPLASMS
Phase: PHASE3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Ovarian cancer trial hopes immunotherapy can buy more time
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel, with or without bevacizumab) can slow the growth of ovarian cancer that has become resistant to platinum-based treatments. About 643 adults with recurrent ovarian, fallopian…
Matched conditions: FALLOPIAN TUBE NEOPLASMS
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC